Sunlamp use is a risk factor for uveal melanoma: a meta-analysis

Weis, Ezekiel; Aghazadeh, Helya; Roelofs, Kelsey A.; Agi, Jorge

doi:10.1016/j.jcjo.2021.02.041

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Use of 'ocular melanoma' is discouraged because it does not differentiate uveal melanoma from melanoma arising from the conjunctiva and eyelid skin. Risk factors for uveal melanoma include light eye and skin colour, cutaneous and iris nevi and freckles, an inability to tan, BAP1 tumour predisposition syndrome, and exposure to arc welding and suntan beds [3][4][5][6][7][8]. Uveal melanoma is the most common primary intraocular malignancy, and the uveal tract is the second most common location for melanoma after the skin [2].…”

Section: Introductionmentioning

confidence: 99%

“…Adverse prognostic factors for survival include altered gene expression profiles, specific mutations, patient age, maximal basal tumour diameter, location, cytogenetic alterations, ciliary body involvement, extrascleral tumour extension, and epithelioid cell type [13][14][15]. Despite advancements in local treatments with improvements in eye-sparing techniques, improvement in survival has not yet been documented [8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Management of Uveal Melanoma: Updated Cancer Care Alberta Clinical Practice Guideline

Weis,

Surgeoner,

Salopek

et al. 2023

Current Oncology

Self Cite

View full text Add to dashboard Cite

Objective: The purpose of this guideline update is to reassess and update recommendations in the prior guideline from 2016 on the appropriate management of patients with uveal melanoma. Methods: In 2021, a multidisciplinary working group from the Provincial Cutaneous Tumour Team, Cancer Care Alberta, Alberta Health Services was convened to update the guideline. A comprehensive review of new research evidence in PubMed as well as new clinical practice guidelines from prominent oncology groups informed the update. An enhancement in methodology included adding levels of evidence and strength of recommendations. The updated guideline was circulated to all members of the Provincial Cutaneous Tumour Team for review and endorsement. Results: New and modified recommendations address provider training requirements, diagnostic imaging for the detection of metastases, neo-adjuvant pre-enucleation radiotherapy, intravitreal anti-vascular endothelial growth factor agents for radiation retinopathy, genetic prognostic testing, surveillance following definitive local therapy, and systemic therapy for patients with metastatic uveal melanoma. Discussion: The recommendations represent evidence-based standards of care agreed to by a large multidisciplinary group of healthcare professionals.

show abstract